Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome.

Blood
Christiane QuerfeldTimothy M Kuzel

Abstract

A phase 2 multicenter trial was performed to evaluate single-agent lenalidomide in advanced, refractory mycosis fungoides/Sézary syndrome. Thirty-two patients were enrolled with a median of 6 prior treatment regimens, including a median of 4 systemic therapies. Patients achieved an overall response rate of 28% (9 patients), and all were partial responses. Median overall survival was 43 months, median progression-free survival was 8 months, and median duration of response was 10 months. No grade 4 toxicities occurred. Grade 3 adverse events included fatigue (22%), infection (9%), and leukopenia (3%). Patients were frequently unable to tolerate the 25-mg starting dose of lenalidomide used in other hematologic malignancies due to fatigue, pain, and transient flare reaction (TFR) as a contributory factor. TFR appeared to correlate with clinical response, but the small sample size limited definitive conclusions, and the underlying mechanisms of this reaction are not known. Data from correlative studies on peripheral blood samples suggest that the effects of lenalidomide could be associated with decreased circulating CD25(+) T cells and CD4(+) T-cell numbers. Skin lesions showed a trend for increased CD8, CD25, and FoxP3 expression w...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Apr 2, 2004·Nature Reviews. Cancer·J Blake BartlettAngus G Dalgleish
Feb 5, 2005·Blood·Rein WillemzeChris J L M Meijer
Feb 11, 2005·The New England Journal of Medicine·Alan ListJerome B Zeldis
Apr 1, 2005·The Journal of Biological Chemistry·Jonathan Whittaker, Linda Whittaker
Jun 3, 2006·The Journal of Investigative Dermatology·Machteld M TiemessenSusan John
Jul 20, 2007·Archives of Dermatology·Vincent D Criscione, Martin A Weinstock
Oct 28, 2008·Pediatric Dermatology·Monica RomeroBarrett Zlotoff
Feb 28, 2009·British Journal of Haematology·Thomas M HabermannJoseph M Tuscano
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 16, 2012·Cancer Chemotherapy and Pharmacology·Angela Segler, Apostolia-Maria Tsimberidou
Sep 18, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Madeleine DuvicH Miles Prince
Jun 5, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franck MorschhauserBertrand Coiffier

❮ Previous
Next ❯

Citations

Jul 16, 2014·Expert Review of Hematology·Jason B KaplanFrancis J Giles
Jan 27, 2016·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniStefano Pileri
Nov 27, 2015·American Journal of Hematology·Ryan A Wilcox
Mar 1, 2016·American Journal of Clinical Dermatology·Sumana Devata, Ryan A Wilcox
May 7, 2016·Blood·Sean WhittakerH Miles Prince
Jul 9, 2016·Current Opinion in Oncology·Julia J Scarisbrick
Sep 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H Miles Prince
Dec 12, 2018·Expert Review of Hematology·Carrie Van Der WeydenH Miles Prince
Jan 12, 2019·Leukemia & Lymphoma·Niloufer Khan, Steven Horwitz
Feb 6, 2018·Current Hematologic Malignancy Reports·Eric Tse, Yok-Lam Kwong
Jul 18, 2019·American Journal of Hematology·Alexandra C HristovRyan A Wilcox
Jan 15, 2020·Der Pathologe·Marion Wobser, Matthias Goebeler
Mar 7, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·Adrienne E KaufmanAmrita Goyal
Sep 13, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Marion Wobser, Matthias Goebeler
Jan 9, 2018·Leukemia & Lymphoma·Jenna JanigaFarah Abdulla
Oct 12, 2018·Leukemia & Lymphoma·Eric FountainNathan Fowler
Jun 14, 2019·Frontiers in Medicine·Tomonori Oka, Tomomitsu Miyagaki
Jun 20, 2018·Frontiers in Oncology·Kazuyasu Fujii
Jul 16, 2019·Current Hematologic Malignancy Reports·Samuel Yamshon, Jia Ruan
Mar 25, 2018·Current Oncology Reports·Louise PhotiouH Miles Prince
Oct 24, 2020·British Journal of Haematology·Julia J ScarisbrickPablo L Ortiz-Romero
Dec 29, 2020·The Australasian Journal of Dermatology·Friyana K BhabhaH Miles Prince
Mar 4, 2021·JAMA Dermatology·Joon Min JungWoo Jin Lee
Mar 4, 2021·Nature Reviews. Clinical Oncology·Max JanBenjamin L Ebert
Apr 10, 2021·International Journal of Dermatology·Natalia Rendón-SernaMaria Bermudez-Muñoz
Apr 29, 2021·Seminars in Hematology·John C Reneau, Ryan A Wilcox
May 15, 2021·British Journal of Haematology·Tarsheen K SethiNishitha Reddy
Jul 24, 2021·American Journal of Hematology·Alexandra C HristovRyan A Wilcox

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.